<a href="https://www.fiercebiotech.com/biotech/lilly-picks-another-vivo-car-t-company-7b-deal-kelonia" hreflang="en">Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B</a>
Eli Lilly has acquired Kelonia Therapeutics for up to $7 billion, including $3.25 billion upfront, to enhance its in vivo CAR-T therapy portfolio, particularly targeting multiple myeloma with the promising KLN-1010 treatment. This acquisition follows Lilly's earlier purchase of Orna Therapeutics and reflects the company's strategy to expand its capabilities in cell therapy amid a competitive landscape.
Eli Lilly's acquisition of Kelonia Therapeutics for up to $7 billion underscores the growing strategic importance of in vivo CAR-T technologies, which promise to simplify and expand access to cell therapies by eliminating the need for individualized manufacturing processes. This move signals a strong investment opportunity in platforms that can deliver rapid and durable responses in a more scalable, off-the-shelf format, thereby addressing significant barriers in current CAR-T treatments. For stakeholders in healthtech and biotech, monitoring advancements in lentiviral vector delivery systems and other in vivo gene placement technologies could provide key insights into future industry trends and investment prospects.